The FDA isn’t the only hurdle for Novartis’ forthcoming CAR-T therapy, which could be the world’s first.
Blog
Less than two weeks after snagging its first FDA nod for Imfinzi, AstraZeneca is out with more positive data for the checkpoint inhibitor.
The FDA isn’t the only hurdle for Novartis’ forthcoming CAR-T therapy, which could be the world’s first.
Less than two weeks after snagging its first FDA nod for Imfinzi, AstraZeneca is out with more positive data for the checkpoint inhibitor.